Approximately 40 fusion partners have been reported to date according to the Atlas of Genetics and Cytogenetics in Oncology and Haematology (https://atlasgeneticsoncology.org/gene/76/ret-(rearranged-during-transfection).[6] A large-scale characterization of Chinese lung cancer revealed a small number of highly prevalent partners, including kinesin family member 5B, coiled coil domain containing 6, and nuclear receptor coactivator 4, which collectively accounted for ~75% of all RET fusions identified in the study.[2] Nonetheless, daily clinical practice continues to uncover new partners. The gene discussed is RET; the disease is lung cancer.